BioNTech Founders to Depart, Form New mRNA-Focused Company
Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.
Editorial Staff Mar 10
Medicine
Latest Medicine stories from Life.
Briefing: Golfer Woodland opens up about PTSD diagnosis
Strategic angle: Gary Woodland reveals his struggle with post-traumatic stress disorder following brain surgery.
Editorial Staff Mar 10
Briefing: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
Editorial Staff Mar 9
Briefing: CRISPR-based technique unlocks healing power of mitochondria for heart failure therapy
Strategic angle: A groundbreaking approach using CRISPR technology shows promise in treating heart failure by enhancing mitochondrial function.
Editorial Staff Mar 9
Briefing: Unlocking the hidden pocket on a billion‑dollar drug target
Strategic angle: Researchers discover new functions of the cereblon protein that could enhance cancer drug efficacy.
Editorial Staff Mar 9
Briefing: A setback for Roche’s breast cancer drug
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Editorial Staff Mar 9
Servier's $2.5 Billion Acquisition of Day One: Strategic Implications
Servier's acquisition of Day One Biopharmaceuticals for $2.5 billion could reshape its position in the pediatric oncology market, but risks remain.
Editorial Staff Mar 6
Strategic view: FDA-UniQure Tussle and Pfizer's Obesity Drug Approval in China
Strategic implications in focus: China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded.
Editorial Staff Mar 6